Real-World Assessment of Relapse Rates in Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a vs Oral Disease-Modifying Drugs

被引：0
|
作者：
Kozma, Chris [1 ]
Munschauer, Frederick [2 ]
Phillips, Amy [2 ]
机构：
[1] CK Consulting Associates LLC, St Helena Isl, SC USA
[2] EMD Serono Inc, Rockland, MA USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.178
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Relapse in Patients with Multiple Sclerosis Newly Initiating scIFNβ1a Compared with Oral Disease-Modifying Drugs: A Real-World Assessment
    Bowen, James
    Kozma, Chris
    Grosso, Megan
    Phillips, Amy
    [J]. NEUROLOGY, 2018, 90
  • [2] Real-world assessment of relapse in patients with multiple sclerosis newly initiating scIFNβ1a compared with oral disease-modifying drugs
    Bowen, J.
    Kozma, C. M.
    Grosso, M.
    Taha, K.
    Phillips, A. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 665 - 665
  • [3] COST ANALYSIS OF PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING SUBCUTANEOUS INTERFERON β-1A VERSUS ORAL DISEASE-MODIFYING DRUGS
    Kozma, C. M.
    Munschauer, F. E.
    Phillips, A. L.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A69 - A69
  • [4] REAL-WORLD ASSESSMENT OF RELAPSE, MEDICAL COSTS AND PERSISTENCY OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH SUBCUTANEOUS INTERFERON β-1A
    Phillips, A. L.
    Locklear, J. C.
    Kozma, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [5] Real-world use of subcutaneous interferon β-1a in patients with relapsing multiple sclerosis
    Beckmann, Yesim
    Uzunkopru, Cihat
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP68 - NP69
  • [6] A Real-World Study of Disease-Modifying Drug Treatment Patterns in US Patients with Multiple Sclerosis Newly Initiating Treatment
    Nicholas, Jacqueline
    Edwards, Natalie C.
    Harlow, Danielle
    Phillips, Amy
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 20
  • [7] Real-world effectiveness of oral disease-modifying therapies for multiple sclerosis
    Thanh Phuong Pham Nguyen
    Thibault, Dylan
    Willis, Allison
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 124 - 125
  • [8] Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
    Alvarez, Enrique
    Nair, Kavita V.
    Tan, Hiangkiat
    Rathi, Kapil
    Gabler, Nicole B.
    Maiese, Eric M.
    Deshpande, Chinmay
    Shao, Qiujun
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 494 - 502
  • [9] Real-world persistence of multiple sclerosis disease-modifying therapies
    Tallantyre, Emma C.
    Dobson, Ruth
    Froud, Joseph L. J.
    St John, Frederika A.
    Anderson, Valerie M.
    Arun, Tarunya
    Buckley, Lauren
    Evangelou, Nikos
    Ford, Helen L.
    Galea, Ian
    George, Sumi
    Gray, Orla M.
    Hibbert, Aimee M.
    Hu, Mo
    Hughes, Stella E.
    Ingram, Gillian
    Kalra, Seema
    Lim, Chia-Hui E.
    Mathews, Joela T. M.
    McDonnell, Gavin V.
    Mescall, Naomi
    Norris, Sam
    Ramsay, Stephen J.
    Rice, Claire M.
    Russell, Melanie J.
    Shawe-Taylor, Marianne J.
    Williams, Thomas E.
    Harding, Katharine E.
    Robertson, Neil P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (07)
  • [10] Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data
    Belotti, Laura Maria Beatrice
    Di Martino, Mirko
    Zenesini, Corrado
    Vignatelli, Luca
    Baldin, Elisa
    Baccari, Flavia
    Ridley, Ben
    Nonino, Francesco
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 80
12345